Curcumin and insulin resistance : molecular targets and clinical evidences

Simple item page
dc.audience students es_MX
dc.audience researchers es_MX
dc.audience teachers es_MX
dc.contributor.author Silvestre Alavez, 0000-0002-9220-0696
dc.contributor.other Jiménez Osorio, Angélica Saraí
dc.contributor.other Monroy, Andrea
dc.coverage MX es_MX
dc.date.accessioned 2018-07-18T03:06:48Z
dc.date.available 2018-07-18T03:06:48Z
dc.date.issued 2016
dc.description Curcumin ((1E,6E)−1,7‐bis(4‐hydroxy‐3‐methoxyphenyl)‐1,6‐heptadiene‐3,5‐dione), the main component of the Indian spice turmeric, has been used in traditional medicine to improve diabetes and its comorbidities. Since the last two decades, scientific research has shown that in addition to its antioxidant properties, curcumin could also work as protein homeostasis regulator and it is able to modulate other intracellular pathways. Curcumin supplementation has been proposed to improve insulin resistance (IR) through the activation of the insulin receptor and its downstream pathways in several experimental models, pointing out that its clinical use may be a good and innocuous strategy to improve IR‐related diseases. IR is associated with many diseases and syndromes like carbohydrate intolerance, diabetes, metabolic syndrome, and cardiovascular disease. Therefore, it is imperative to identify safe therapeutic interventions aimed to reduce side effects that could lead the patient to leave the treatment. To date, many clinical trials have been carried out using turmeric and curcumin to improve metabolic syndrome, carbohydrate intolerance, diabetes, and obesity in individuals with IR. Results so far are inconclusive because dose, time of treatment, and type of curcumin can change the study outcome significantly. However, there is some clinical evidence suggesting a beneficial effect of curcumin on IR. In this review, we discuss the factors that could influence curcumin effects in clinical trials aimed to improve IR and related diseases, and the conclusions that can be drawn from results obtained so far. es_MX
dc.format application/pdf es_MX
dc.identificador.materia 3 es_MX
dc.identifier.other http://dx.doi.org/10.1002/biof.1302
dc.identifier.uri http://hdl.handle.net/20.500.12222/233
dc.language eng es_MX
dc.publisher Universidad Autónoma Metropolitana. Unidad Lerma es_MX
dc.rights Attribution-NonCommercial-NoDerivatives 4.0 Internacional *
dc.rights.license info:eu-repo/semantics/openAccess es_MX
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/ es_MX
dc.subject MEDICINA Y CIENCIAS DE LA SALUD es_MX
dc.subject.keywords Diabetes es_MX
dc.subject.keywords Curcumin es_MX
dc.subject.keywords Insulin resistance es_MX
dc.subject.keywords Obesity es_MX
dc.subject.keywords Prediabetes es_MX
dc.subject.keywords Diabetes es_MX
dc.title Curcumin and insulin resistance : molecular targets and clinical evidences es_MX
dc.type preprint es_MX
dc.type.version info:eu-repo/semantics/publishedVersion es_MX
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
000070.pdf
Size:
189.77 KB
Format:
Adobe Portable Document Format
Description:
Download
No Thumbnail Available
Name:
000070.xml
Size:
217.98 KB
Format:
Extensible Markup Language
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos Científicos